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Summary
Objective: Loss of articular cartilage and intervertebral disc function in arthritis or disc degeneration is associated with degradation of the pro-
teoglycan (PG) aggregates by either proteolysis of aggrecan or hyaluronan (HA) degradation. The aim of this work was to determine whether
degradation of HA in PG aggregate degradation is inﬂuenced by link protein (LP) stabilization of the PG aggregates.
Methods: Aggrecan and LP were prepared from fetal bovine epiphyseal cartilage, and PG aggregates were formed in the presence or ab-
sence of LP. The PG aggregates were exposed to hyaluronidase or free radicals to promote HA degradation. Degradation of HA, aggrecan
and LP were assessed by gel ﬁltration chromatography and polyacrylamide gel electrophoresis.
Results: High concentrations of hyaluronidase cleaved both PG aggregates between each aggrecan molecule, whereas low concentrations
gave much less cleavage of the LP-stabilized aggregate. High free radical concentrations gave extensive cleavage of all components of both
PG aggregates, whereas low concentrations are more selective for HA damage and to a much lesser extent in the LP-stabilized aggregates.
Thus the presence of LP caused a diminution in the capacity of both catabolic agents to degrade HA as long as levels of the degradative
agents were not excessive.
Conclusion: In addition to stabilizing the PG aggregates towards dissociation, LP may also help protect the PG aggregates from degradation
under conditions where tissue catabolism is promoted.
ª 2006 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Proteoglycan (PG) aggregates form a major constituent of
the extracellular matrix of hyaline cartilage1,2 and interverte-
bral disc3, where their osmotic properties provide tissue
turgidity and the ability to resist compression. The major
PG aggregate in these tissues is composed of aggrecan,
link protein (LP) and hyaluronan (HA). Aggrecan is a mem-
ber of the hyalectan family of PGs that are able to interact
with HA via conserved amino-terminal globular (G1) do-
mains4. Other family members include versican, neurocan
and brevican, but only aggrecan and versican have been
described in cartilage and disc, and of these aggrecan
predominates5. In addition to its G1 domain, aggrecan
possesses additional globular domains and glycosamino-
glycan (GAG)-binding domains along its core protein6e9.
The GAGs are chondroitin sulfate (CS) and keratan sulfate
(KS). In a typical newly synthesized PG aggregate, up to
100 aggrecan molecules may be associated with a single
HA molecule. Each aggrecan/HA interaction can be stabi-
lized by the additional interaction of LP10.
LP may also be considered as a hyalectan as its protein
structure is analogous to the G1 region of aggrecan and the
other aggregating PGs11,12. The term LP is commonly used
to describe the molecule present in cartilage and disc that
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Received 5 October 2005; revision accepted 9 February 2006.823is found in association with aggrecan and HA, though there
are four structurally related LPs in the human and mouse
genome13. At the genomic level each LP gene is adjacent
to one of the hyalectan PG genes. This does not, however,
mean that there is coordinate expression of the LP and its
partnerPGand that theyalways reside in the samePGaggre-
gate. The cartilage LP gene for example lies adjacent to the
versican gene rather than the aggrecan gene. In addition to
stabilizing the PG aggregates, LP is also required during
aggregate formation to promote the interaction between ag-
grecan andHA. The newly synthesized aggrecanG1 domain
is not able to interact with HA until it undergoes a conforma-
tional change e a phenomenon known as delayed aggrega-
tion14. The conformational change can be induced by LP15.
PG aggregate function is dependent on both its highly
anionic nature and its size, which in turn are dependent
on the GAG content of aggrecan and the length of the
HA, respectively. The high charge density present on
each aggrecan molecule causes the molecules to swell in
aqueous solution, which provides the ability to resist com-
pressive loads1. A large HA length ensures maximal size
for the aggregates, which probably limits their diffusion
within the tissue, resulting in a localized ﬁxed charge den-
sity. Any metabolic process which results in a diminution
of PG aggregate charge or size is likely to be detrimental
to tissue function. Proteolytic degradation of aggrecan is
commonly associated with the loss of tissue function occur-
ring in arthritis16,17 and degenerative disc disease18,19, as it
promotes the generation of GAG-containing fragments of
aggrecan that are no longer bound to HA. Such fragments
are susceptible to loss by diffusion from the tissue.
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the ADAMTS family20, play a major role in such degrada-
tion21e23. However, there is evidence that HA degradation
can also occur, particularly under conditions of joint inﬂam-
mation24. Two mechanisms may account for HA degrada-
tion, the action of hyaluronidases25 or free radicals26.
The participation of LP in a PG aggregate causes the HA
to adopt an extended conformation27,28, and essentially
results in a protein coat covering the HA surface. It is not
unreasonable to suggest that such a coat may limit access
of the relatively large hyaluronidase to the HA surface or
scavenge free radicals before they gain access to the HA
surface. The purpose of the present work was to test this
hypothesis by comparing the ability of hyaluronidase and
free radicals to degrade PG aggregates that are either
devoid of LP or stabilized by LP.
Methods
PREPARATION OF PG AGGREGATES
Fetal bovine epiphyseal cartilage (BEC) (10 g) was ﬁnely
divided using a scalpel into pieces that were 1e2 mm in
each dimension, then extracted with 4 M guanidinium
chloride, 0.1 M sodium acetate, pH 6.0, containing protein-
ase inhibitors (100 ml)29. Extraction was for 48 h at 4(C
with continuous stirring. The extract was then ﬁltered
through glass wool to remove the cartilage residue, and
HA (1 mg dissolved in 1 ml 0.1 M sodium acetate, pH 6.0)
was added to the clariﬁed extract. The extract was then di-
alyzed against 0.1 M sodium acetate, pH 6.0, to remove the
guanidine and produce associative conditions under which
PG aggregate formation can occur. CsCl (0.8 g/ml extract)
was added to give a density of 1.5 g/ml, and the solution
centrifuged at 100,000 g for 48 h at 10(C30. The resulting
density gradients were fractionated, and fractions with
a density greater than 1.6 g/ml were pooled, then dialyzed
exhaustively against water before freeze drying. The yield
was 360 mg (A1-preparation).
The A1-preparation (300 mg) was resuspended in 100 ml
4 M guanidinium chloride, and CsCl (76 g) was added to
give a density of 1.5 g/ml29. This mixture was subjected to
density gradient centrifugation and fractionation as above.
Fractions with a density greater than 1.55 g/ml (aggrecan)
and those with a density less than 1.45 g/ml (LP) were
pooled separately. The presence of aggrecan and LP was
conﬁrmed by GAG analysis and immunoblotting, respec-
tively. The intermediate fractions containing HA were
discarded. The aggrecan solution was divided into two
equal parts, both of which were supplemented with HA
(2 mg). One part was also supplemented with the LP solu-
tion. Both solutions were then dialyzed exhaustively against
water and freeze dried. This yielded LP-free (110 mg) and
LP-stabilized (120 mg) PG aggregate preparations (Fig. 1).
The amount of HA used to form the PG aggregates was
chosen to be 1.5e2% by weight of the aggrecan, which is
reported to give maximum aggregation for HA/aggrecan
complexes31. This HA content may be excessive for maxi-
mal substitution by aggrecan in LP-stabilized aggregates.
However, the presence of excess LP could result in the
occupation of some free binding sites on the HA.
HYALURONIDASE DIGESTION
Hyaluronidase (from Streptomyces hyalurolyticus, 100 U/
vial, ICN) was resuspended in 4.0 ml H2O (0.025 U/ml). ThePG aggregate preparations were resuspended at 1 mg/ml in
20 mM sodium acetate, pH 6.0, containing 150 mM NaCl.
Hyaluronidase (20 or 2 ml per 1 ml PG solution) was added
to give 0.5 or 0.05 U/mg PG aggregate. The mixtures were
then incubated at 37(C for 1 h, before analysis by
Sephacryl S-1000 chromatography.
HYDROGEN PEROXIDE-INDUCED DEGRADATION
PG aggregate preparations were dissolved at 1 mg/ml in
25 mM sodium acetate, pH 5.6, containing 80 mM NaCl32.
Digestion was carried out with 10 or 1 ml 30% hydrogen
peroxide (Sigma) per ml PG solution, to give a ﬁnal hydro-
gen peroxide concentration of 0.3 or 0.03%, respectively. In
some cases 1 mM CuSO4 was added to the incubation
buffer. Solutions were incubated at 37(C for 20 h, and
degradation was terminated by the addition of diethylene-
triaminopenta-acetic acid (DETPA, Sigma) to a ﬁnal con-
centration of 1 mM. The DETPA was prepared as
a 100 mM stock solution in 1 M HCl. In some cases DETPA
was added prior to the addition of hydrogen peroxide.
SEPHACRYL S-1000 CHROMATOGRAPHY
Sephacryl S-1000 resin (Amersham Biosciences) was
packed into a 120 1.0 cm column with a bed volume of
90 ml. The resin was equilibrated in 200 mM sodium
acetate, pH 5.5. The intact or digested PG aggregate prep-
arations (1 mg in 1 ml of the same buffer) were loaded on
the column, then eluted at a ﬂow rate of 5 ml/h. Fractions
(1 ml) were collected and analyzed for GAG content.
Selected fractions were also analyzed by SDS/polyacryl-
amide gel electrophoresis (PAGE) and immunoblotting for LP.
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PG Aggregate
dissociative CsCI
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Fig. 1. Scheme of PG aggregate preparation. Aggrecan and LP
were isolated from a PG aggregate preparation derived from fetal
BEC. Aggrecan was mixed with HA to yield LP-free PG aggregates,
and with both HA and LP to yield LP-stabilized PG aggregates.
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Samples were analyzed by SDS/PAGE under reducing
conditions in Nu Page 10% BiseTris gels (Invitrogen) using
a MOPS buffer system, as described by the manufacturer.
Prior to analysis, samples were mixed with sample buffer
and incubated at 70(C for 10 min. Following electrophoresis,
proteins were electroblotted onto nitrocellulose (BioRad),
using the Nu Page transfer buffer with 10%methanol. Trans-
fer was at 30 V for 2 h. Following blocking of the membranes
in 5% skim milk, LP was detected using the ECL system
(Amersham). The primary antibody was a mouse monoclo-
nal speciﬁc for LP (8A4, Developmental Studies Hybridoma
Bank) used at a 1:5000 dilution. The secondary antibody was
a biotinylated anti-mouse IgG used at a 1:1000 dilution.
GAG ANALYSIS
GAG analysis was carried out using the dimethyl methy-
lene blue (DMMB)-dye binding assay33 adapted for use with
96 well plates.
Results
Intact PG aggregate preparations were analyzed by gel
ﬁltration chromatography using Sephacryl S-1000. This
resin was chosen as it permits PG aggregates to be
resolved from intact aggrecan and their degradation prod-
ucts. Analysis of the LP-stabilized material revealed a proﬁle
where 75e80% of the GAG content eluted at or near the
void volume of the column [Fig. 2(A)] indicative of PG
aggregates. Analyses of the LP-free material indicated that
65e70% of the GAG content eluted in a position compatible
with PG aggregates. However, a greater proportion of these
aggregates were eluted in the included volume, indicating
a smaller average size range than for the LP-stabilized
aggregates. The smaller aggregate size could reﬂect a lower
degree of aggrecan substitution or partial dissociation
during the chromatography. Analysis by SDS/PAGE veriﬁed
that LP was indeed associated with the LP-stabilized aggre-
gates but absent from those prepared LP free [Fig. 2(B)].
Digestion of either PG aggregate preparation with a high
concentration of Streptomyces hyaluronidase, which is
speciﬁc for the cleavage of HA34, produced degradation
products of equivalent size. These degradation products
eluted in a position compatible with intact aggrecan
molecules [Fig. 3(A)], indicating cleavage of the HA in the
regions between each aggrecan attachment site. Analysis
by SDS/PAGE revealed that the aggrecan molecules from
the LP-stabilized aggregates were still associated with LP
[Fig. 4(A)], implying that they remain bound to HA frag-
ments. There was no evidence for the presence of free
LP or LP/HA fragment complexes devoid of aggrecan,
which would be expected to elute between the elution posi-
tion of aggrecan and the total volume of the column. It is
therefore likely that the aggregates do not possess an
excess of LP relative to aggrecan. In contrast, treatment
of the two PG aggregate preparations at one-tenth the
hyaluronidase concentration used above produced dis-
tinctly different results. The LP-free aggregates continued
to show extensive degradation, although many of the degra-
dation products were less retarded than those generated
with the higher hyaluronidase concentration [Fig. 3(B)].
This indicates that cleavage has not occurred between ev-
ery aggrecan molecules and that some mini-aggregates
persist. The LP-stabilized aggregate products exhibited
a markedly different proﬁle that was more akin to the intactstarting material, although the proportion of smaller compo-
nents was slightly increased [Fig. 4(B)].
Digestion with hydrogen peroxide, as a source of reactive
oxygen species/free radicals32, yielded Sephacryl S-1000
proﬁles that were distinct from those observed with
hyaluronidase. Treatment with a high hydrogen peroxide
concentration showed extensive degradation of both aggre-
gate preparations, although the extent of degradation was
greater with the LP-free PG aggregates [Fig. 5(A)]. Both
aggregate preparations showed a bimodal distribution of
degradation products with material eluting at the total
volume of the column and between this and the elution
position of the intact monomer. This implies that the aggre-
can monomers themselves have undergone degradation.
Elution at the total column volume indicates a degradation
product that is equivalent in size or smaller than intact CS
chains. It is likely that degradation has occurred not only
within HA, but also within the core protein and GAG chains
of aggrecan. Treatment of the PG aggregate preparations
with one-tenth the hydrogen peroxide concentration used
above, yielded a vastly different scenario, with neither
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Fig. 2. Analysis of intact PG aggregates. LP-free and LP-stabilized
PG aggregates were analyzed by gel ﬁltration through Sephacryl S-
1000 (A). Column fractions were analyzed for GAG content by the
DMMB-dye binding assay. The void (Vo) and total (Vt) volumes of
the column and the elution position of aggrecan are indicated. The
fractions from gel ﬁltration analysis of the LP-stabilized PG aggre-
gate were analyzed for LP content by SDS/PAGE and subsequent
immunoblotting for LP (B). The migration position of the two glyco-
sylation variants of intact LP (LP1 and LP2) is indicated.
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cleavage [Fig. 5(B)]. The LP-free aggregates yielded a bi-
modal proﬁle with the majority of products eluting with
a size equivalent to intact aggrecan and the remainder elut-
ing between this position and the void volume. This
is indicative of partial HA degradation with cleavage
between each aggrecan molecule being incomplete. The
LP-stabilized aggregates showed minimal degradation
with the majority of the material still eluting at the void
volume of the column. This is a similar scenario to that
observed with the low concentration of hyaluronidase.
Increasing free radical production from the high hydrogen
peroxide concentration, via the addition of 1 mM copper
sulfate, resulted in the degradation of the LP-stabilized
PG aggregates being as extensive as that of the LP-free
aggregates with hydrogen peroxide alone [Fig. 5(C)], which
appears to be the limit of degradation achievable. Under
these conditions LP degradation appears to be extensive
as no immunologically reactive LP was detectable by
SDS/PAGE and immunoblotting (Fig. 6). In contrast, the
low hydrogen peroxide concentration alone caused only
minimal LP degradation and the high hydrogen peroxide
concentration alone caused an intermediate degree of
degradation. As expected, hyaluronidase does not alter
LP structure. The ability of hydrogen peroxide to cause
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0.15
0.2
0.25
0.3 Aggrecan
Aggrecan
Vo Vt
H’ase 0.5 U
-LP
+LP
H’ase 0.05 U
-LP+LP
A
B
A 5
30
 n
m
A 5
30
 n
m
1 6 11 16 21 26 31 36 41 46 51 56 61 66 71 76 81 86 91
0
0.05
0.1
0.15
0.2
0.25
0.3
Vo Vt
Fraction Number
Fig. 3. Gel ﬁltration analysis of PG aggregates after hyaluronidase
treatment. LP-free and LP-stabilized PG aggregates were analyzed
by gel ﬁltration through Sephacryl S-1000 following treatment with
0.5 units (A) or 0.05 units (B) Streptomyces hyaluronidase per mg
PG. Column fractions were analyzed for GAG content by the
DMMB-dye binding assay. The void (Vo) and total (Vt) volumes
of the column and the elution position of aggrecan are indicated.LP cleavage could be inhibited by the presence of DETPA,
a metal ion chelator, indicating that degradation is probably
occurring as a result of hydroxyl radical generation (Fig. 6).
DETPA is also able to prevent the decrease in PG aggre-
gate size brought about by hydrogen peroxide, indicating
that HA cleavage is also a hydroxyl radical-mediated event.
Discussion
The present work provides evidence of a new function for
LP in PG aggregates. In addition to the previously
described roles in relation to aggregate stabilization and
delayed aggregation, it also appears that LP can help pro-
tect the aggregates from degradation via HA catabolism.
Such protection exists for degradation mediated by hyal-
uronidase or free radicals, but is not absolute as protection
ceases when high concentrations of hyaluronidase or radi-
cals are present. Thus, while degradation may be retarded
by LP when HA is exposed to limited hyaluronidase or rad-
ical levels, it is not abolished.
The origin of this protection may relate to the fact that LP-
stabilized PG aggregates can possess a continuous protein
coat over the HA chain27,28. This coat may limit access of
hyaluronidase to the HA by steric blocking (Fig. 7). Such
a mechanism is, however, less likely with small free radi-
cals. It has, however, been shown that LP can act as
a free radical scavenger32, and it may therefore provide
protection by acting as a more available target for radical
Fraction number
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Fig. 4. SDS/PAGE analysis of LP after hyaluronidase treatment.
The fractions from gel ﬁltration analysis of the LP-stabilized PG ag-
gregate treated with 0.5 units (A) or 0.05 units (B) hyaluronidase
(see Fig. 3) were analyzed for LP content by SDS/PAGE and sub-
sequent immunoblotting for LP. The migration position of the two
glycosylation variants of intact LP (LP1 and LP2) is indicated.
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work, as increasing radical ﬂuxes do indeed modify the LP
in the PG aggregates, ultimately resulting in its complete
destruction. It is likely that the LP-stabilized aggregates
used in this work do not possess a continuous protein
coat over all their length due to incomplete aggrecan substi-
tution in vitro, and this could contribute to their susceptibility
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Fig. 5. Gel ﬁltration analysis of PG aggregates following H2O2 treat-
ment. LP-free and LP-stabilized PG aggregates were analyzed by
gel ﬁltration through Sephacryl S-1000 following treatment with
0.3% (A) or 0.03% (B) H2O2. In addition, LP-stabilized PG aggre-
gates were analyzed following treatment with 0.3% H2O2 in the
presence of 1 mM CuSO4 (C). Column fractions were analyzed for
GAG content by the DMMB-dye binding assay. The void (Vo) and
total (Vt) volumes of the column and the elution position of aggre-
can are indicated.to cleavage by the higher hyaluronidase and radical con-
centrations. In the case of the LP-free aggregates, access
to hyaluronidases or free radicals may be enhanced by an
incomplete protein coat on the HA chain due to both the
absence of LP and the possible reversible dissociation of
aggrecan when it does not participate in a LP-stabilized
interaction31.
While PG aggregates prepared in vitro commonly contain
LP, it is not clear that all aggregates exist in this state
in vivo. When PG aggregates are allowed to reform following
dissociative extraction, an average composition of aggre-
can, HA and LP ensues. However, when PG aggregates
have been isolated directly from the cartilage extracellular
matrix, two forms of aggregates have been shown to be
present35. The difference between these two forms appears
to be the absence and presence of LP36. Thus both LP-free
and LP-stabilized PG aggregates may be present in carti-
lage in vivo. If these different aggregates do not occur in
a uniform distribution, then the susceptibility to PG aggre-
gate turnover will vary at different sites within the tissue. It
is also possible that a spectrum of PG aggregates with vary-
ing degrees of substitution by aggrecan and LP is present in
the cartilage extracellular matrix. If so, one would predict
that their susceptibility to cleavage by hyaluronidases or
free radicals would increase as their degree of substitution
decreases.
Ultimately the extent of PG aggregate turnover via HA
degradation will depend on the production of hyaluronidase
or free radicals. The human genome contains several hyal-
uronidase genes25, some of which have been shown to be
expressed by chondrocytes37. While hyaluronidases are of-
ten associated with the lysosomal degradation of PGs, it is
feasible that some types could operate in the extracellular
milieu and that their production could be stimulated by
IL-138. However, at present there is no direct evidence to
prove that hyaluronidase-mediated extracellular degrada-
tion is a reality in cartilage. With respect to free radicals,
there is evidence that chondrocytes can produce both su-
peroxide and hydrogen peroxide39,40. While neither of these
species may cause direct damage to the PG aggregates,
1 2 3 4 5 6
LP1
LP2
Fig. 6. SDS/PAGE analysis of LP following H2O2 treatment. LP-
stabilized PG aggregate was digested with H2O2 or hyaluronidase,
then analyzed for LP content by SDS/PAGE and subsequent immu-
noblotting for LP. The migration position of the two glycosylation
variants of LP (LP1 and LP2) is indicated. Samples are from (1)
no treatment, or treatment with (2) 0.03% H2O2, (3) 0.3% H2O2,
(4) 0.3% H2O2 plus 1 mM CuSO4, (5) treatment with 0.5 units hyal-
uronidase, and (6) treatment with 0.3% H2O2 plus DETPA.
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hydroxyl radical formation from hydrogen peroxide26.
Alternatively, superoxide may react with nitric oxide to
form peroxynitrite41. This may be particularly prevalent un-
der conditions of joint inﬂammation, where cytokines such
as IL-1 promote nitric oxide formation42,43. Both hydroxyl
radicals and peroxynitrite are highly reactive, and both
may be produced in conditions such as haemophilia44,45,
where both iron and inﬂammation are present in the joint.
Radical-mediated degradation of LP in the PG aggregates
of human cartilage is thought to occur slowly throughout
life32,46, but at present there is no evidence for increased
action in pathology. It has also been shown that HA degra-
dation can occur within the PG aggregates of some carti-
lage in response to IL-124,47, but it is unclear whether this
is mediated by free radicals or hyaluronidase.
At present, it is impossible to know whether the presence
of LP-free or LP-stabilized PG aggregates in cartilage is by
design or chance. In principle, such diversity does permit
selective turnover of the PG aggregates, via HA degrada-
tion, a situation that does not occur with aggregate degrada-
tion mediated by proteinases. However, the physiological
relevance of this phenomenon remains to be established.
LP-Free PG Aggregate
LP-Stabilized PG Aggregate
Aggrecan
HA
Incomplete protein
coat on HA allows
access for
hyaluronidase
and radicals
LP
Contiguous protein
coat on HA limits
access for
hyaluronidase
and radicals
Fig. 7. Diagmatic representation of LP function. PG aggregates are
depicted as central cores of HA interacting with multiple aggrecan
molecules that are packed maximally. LP-free aggregates are de-
picted with spaces between aggrecan molecules that allow ready
access for hyaluronidases or free radicals. LP-stabilized aggre-
gates are depicted as possessing a continuous protein coat along
the HA which limits hyaluronidase or free radical action. In reality,
LP-stabilized aggregates may possess a lower degree of aggre-
can/LP substitution and would possess an incomplete protein
coat and have an increased susceptibility to hyaluronidase or
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